Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 197

1.

Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Mishra J, Madhubala R, Singh S.

Parasitol Res. 2013 Mar;112(3):1001-9. doi: 10.1007/s00436-012-3222-1. Epub 2012 Dec 18.

PMID:
23242321
[PubMed - indexed for MEDLINE]
2.

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.

Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P.

PLoS Negl Trop Dis. 2012;6(5):e1657. doi: 10.1371/journal.pntd.0001657. Epub 2012 May 22.

PMID:
22629478
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.

Mandal S, Maharjan M, Singh S, Chatterjee M, Madhubala R.

J Antimicrob Chemother. 2010 Mar;65(3):496-507. doi: 10.1093/jac/dkp468. Epub 2010 Jan 12.

PMID:
20067981
[PubMed - indexed for MEDLINE]
Free Article
4.

Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.

Subba Raju BV, Gurumurthy S, Kuhls K, Bhandari V, Schnonian G, Salotra P.

Parasitol Res. 2012 Oct;111(4):1559-68. Epub 2012 Jul 1.

PMID:
22752721
[PubMed - indexed for MEDLINE]
5.

Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.

Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P.

J Infect Dis. 2006 Aug 1;194(3):302-6. Epub 2006 Jun 22.

PMID:
16826477
[PubMed - indexed for MEDLINE]
Free Article
6.

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.

Pandey K, Das VN, Singh D, Das S, Lal CS, Verma N, Bimal S, Topno RK, Siddiqui NA, Verma RB, Sinha PK, Das P.

J Clin Microbiol. 2012 Apr;50(4):1478-9. doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.

PMID:
22278840
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.

Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N.

J Immunol. 2007 Oct 15;179(8):5592-603.

PMID:
17911647
[PubMed - indexed for MEDLINE]
Free Article
8.

Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.

Singh RP, Picado A, Alam S, Hasker E, Singh SP, Ostyn B, Chappuis F, Sundar S, Boelaert M.

Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.

PMID:
22882665
[PubMed - indexed for MEDLINE]
Free Article
9.

Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.

Dey A, Singh S.

Infect Genet Evol. 2007 Mar;7(2):219-22. Epub 2006 Oct 5.

PMID:
17027344
[PubMed - indexed for MEDLINE]
10.

In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Kumar D, Kulshrestha A, Singh R, Salotra P.

Antimicrob Agents Chemother. 2009 Feb;53(2):835-8. doi: 10.1128/AAC.01233-08. Epub 2008 Nov 17.

PMID:
19015344
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Leishmania species, drug unresponsiveness and visceral leishmaniasis in Bihar, India.

Thakur CP, Dedet JP, Narain S, Pratlong F.

Trans R Soc Trop Med Hyg. 2001 Mar-Apr;95(2):187-9.

PMID:
11355558
[PubMed - indexed for MEDLINE]
12.

Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.

Das VN, Pandey K, Singh D, Forwood C, Lal CS, Das P.

J Postgrad Med. 2013 Jul-Sep;59(3):226-8. doi: 10.4103/0022-3859.118046.

PMID:
24029204
[PubMed - indexed for MEDLINE]
Free Article
13.

Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D.

J Infect Dis. 1999 Aug;180(2):564-7.

PMID:
10395884
[PubMed - indexed for MEDLINE]
Free Article
14.

Studies on stibanate resistant Leishmania donovani isolates of Indian origin.

Pal S, Mandal A, Duttagupta S.

Indian J Exp Biol. 2001 Mar;39(3):249-54.

PMID:
11495284
[PubMed - indexed for MEDLINE]
15.

DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal Leishmaniasis in humans.

Sreenivas G, Raju BV, Singh R, Selvapandiyan A, Duncan R, Sarkar D, Nakhasi HL, Salotra P.

J Clin Microbiol. 2004 Apr;42(4):1739-41.

PMID:
15071036
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.

Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, Das P, Bhattacharya SK, Sinha A.

Indian J Med Res. 2008 Jul;128(1):38-44.

PMID:
18820357
[PubMed - indexed for MEDLINE]
17.

Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.

Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, Dujardin JC, Rijal S, Vanaerschot M.

MBio. 2013 Oct 8;4(5):e00611-13. doi: 10.1128/mBio.00611-13.

PMID:
24105765
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs.

Prajapati VK, Mehrotra S, Gautam S, Rai M, Sundar S.

Am J Trop Med Hyg. 2012 Oct;87(4):655-7. doi: 10.4269/ajtmh.2012.12-0022. Epub 2012 Aug 27.

PMID:
22927497
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Hepatitis B and C viral infections in Indian kala-azar patients receiving injectable anti-leishmanial drugs: a community-based study.

Singh S, Kumar J, Singh R, Dwivedi SN.

Int J Infect Dis. 2000;4(4):203-8.

PMID:
11231183
[PubMed - indexed for MEDLINE]
20.

Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.

Sinha PK, Ranjan A, Singh VP, Das VN, Pandey K, Kumar N, Verma N, Lal CS, Sur D, Manna B, Bhattacharya SK.

J Infect. 2006 Jul;53(1):60-4. Epub 2005 Nov 2.

PMID:
16269185
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk